KALA BIO (NASDAQ:KALA) Lowered to Neutral Rating by LADENBURG THALM/SH SH

LADENBURG THALM/SH SH downgraded shares of KALA BIO (NASDAQ:KALA) from a buy rating to a neutral rating in a report published on Monday morning, MarketBeat.com reports.

A number of other equities analysts have also recently commented on KALA. Lifesci Capital upgraded KALA BIO to a “strong-buy” rating in a report on Wednesday, September 3rd. Wall Street Zen lowered shares of KALA BIO from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. Oppenheimer upped their target price on shares of KALA BIO from $15.00 to $33.00 and gave the stock an “outperform” rating in a research note on Thursday, September 11th. HC Wainwright increased their target price on shares of KALA BIO from $12.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, September 17th. Finally, Mizuho initiated coverage on shares of KALA BIO in a research note on Monday, September 8th. They issued an “outperform” rating and a $30.00 price target for the company. One investment analyst has rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, KALA BIO has an average rating of “Hold” and an average price target of $20.38.

KALA BIO Stock Down 11.1%

KALA BIO stock opened at $1.36 on Monday. The company has a market capitalization of $9.55 million, a PE ratio of -0.20 and a beta of -2.09. The company has a debt-to-equity ratio of 3.19, a quick ratio of 2.10 and a current ratio of 2.10. KALA BIO has a fifty-two week low of $1.10 and a fifty-two week high of $20.60. The firm has a 50 day moving average price of $11.14 and a 200 day moving average price of $6.81.

KALA BIO (NASDAQ:KALA) last released its quarterly earnings results on Friday, August 8th. The company reported ($1.71) EPS for the quarter, topping analysts’ consensus estimates of ($1.82) by $0.11. Research analysts expect that KALA BIO will post -10.84 earnings per share for the current year.

Institutional Investors Weigh In On KALA BIO

A number of hedge funds and other institutional investors have recently modified their holdings of KALA. ADAR1 Capital Management LLC grew its stake in shares of KALA BIO by 35.7% during the first quarter. ADAR1 Capital Management LLC now owns 298,955 shares of the company’s stock worth $1,713,000 after purchasing an additional 78,582 shares in the last quarter. Readystate Asset Management LP acquired a new position in shares of KALA BIO during the 1st quarter worth about $243,000. AIGH Capital Management LLC increased its holdings in shares of KALA BIO by 61.9% in the 1st quarter. AIGH Capital Management LLC now owns 196,350 shares of the company’s stock valued at $1,125,000 after acquiring an additional 75,048 shares during the last quarter. Woodline Partners LP acquired a new stake in shares of KALA BIO during the 1st quarter worth about $1,483,000. Finally, Geode Capital Management LLC lifted its stake in KALA BIO by 2.8% during the second quarter. Geode Capital Management LLC now owns 56,367 shares of the company’s stock worth $268,000 after purchasing an additional 1,534 shares during the last quarter. 24.61% of the stock is currently owned by institutional investors and hedge funds.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.